# InSilico Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/insilico-medicine

- Industry: Biotechnology
- Headquarters: Hong Kong, Hong Kong SAR - China
- Website: www.insilico.com
- Total disclosed funding: $497M
- Latest round: Series E (Mar 13, 2025)
- Investors on record: 31

## About

Based in Hong Kong, and founded in 2014, Yingsi Intelligent Technology (Shanghai) Co., Ltd., dba InSilico Medicine, operates an artificial intelligence platform for drug development to treat cancer and age-related diseases. The company was founded by its CEO, Alex Zhavoronkov. The company has its R&D operations in the USA, Belgium, Russia, UK, Taiwan, and China. The company’s Chairman, Executive Director and CEO, Alex Zhavoronkov, published over 150 peer-reviewed research papers and 2 books, including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Macmillan, 2013). In December 2025, InSilico Medicine raised HKD 2.28 billion in IPO, selling 94.69 million shares at HKD 24.05 per share on the Hong Kong Exchanges and Clearing Limited, under ticker "03696".
 InSilico Medicine provides drug discovery engines used in the drug development process, digital medicine, and finding novel solutions for age-related and severe diseases using genomics and big data analysis. The company also provides drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s diseases, and Alzheimer’s diseases. InSilico Medicine's products include PandaOmics, a multinomial target discovery, a deep biology engine that enables disease target identification, Chemistry42, the generation of synthetic biology and novel molecules' data, and InClinico for predicting trial outcomes. The company generates revenue by providing AI-driven drug discovery services and software through its Pharma.AI platform and by developing and potentially licensing its own preclinical product pipelines. The company will use the March 2025 funding for optimization of artificial intelligence models and algorithms, upgrade and build automated robotic laboratories, further clinical validation of the leading anti-idiopathic pulmonary fibrosis drug ISM001-055, and efficient advancement and continuous exploration of other self-developed or cooperative drug R&D pipelines.

## Funding rounds

- Series E, Mar 13, 2025, $110M — Warburg Pincus, Aramco Ventures, Wuxi Huading Venture Capital, Value Partners Group, Pudong Venture Capital, Yixing Yicai Private Equity Fund Management, Shanghai Pudong Development (Group) Co., Ltd., Dahong Investment Co., Ltd.
- Series D, Aug 10, 2022, $35M — Warburg Pincus, Qiming Venture Partners, WS Investments, BOC International, Pavilion Capital, Deerfield Management, Aramco Ventures, BOLD Capital Partners, B Capital
- Series D, Jun 6, 2022, $60M — Warburg Pincus, Qiming Venture Partners, BOC International, Pavilion Capital, Deerfield Management, BOLD Capital Partners, B Capital
- Series C, Jun 22, 2021, $255M — OrbiMed Advisors, Hong Shan, Warburg Pincus, CPE Capital, Qiming Venture Partners, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, President International Development Corporation, Pavilion Capital, Deerfield Management, Maison Capital, BOLD Capital Partners, B Capital, Baidu Ventures, Lake Bleu Capital, Formic Ventures, Sage Partners, Mirae Asset Capital Markets
- Series B, Apr 20, 2020 — Harmonix
- Series B, Sep 9, 2019, $37M — Qiming Venture Partners, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Eight Roads Ventures, Pavilion Capital, BOLD Capital Partners, Baidu Ventures
- Series B, Aug 12, 2019 — Formic Ventures
- Seed, Nov 1, 2015 — Deep Knowledge Ventures
- Seed, Apr 16, 2014 — Deep Knowledge Ventures

## Investors

- Deep Knowledge Ventures (https://capitalatlas.ai/funds/deep-knowledge-ventures) — Seed
- Formic Ventures (https://capitalatlas.ai/funds/formic-ventures) — Series B, Series C
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B, Series C, Series D
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B, Series C
- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Series B, Series C
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series B, Series C
- Pavilion Capital — Series B, Series C, Series D
- BOLD Capital Partners (https://capitalatlas.ai/funds/bold-capital-partners) — Series B, Series C, Series D
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series B, Series C
- Harmonix — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Hong Shan — Series C
- Warburg Pincus (https://capitalatlas.ai/funds/warburg-pincus) — Series C, Series D, Series E
- CPE Capital (https://capitalatlas.ai/funds/cpe-capital) — Series C
- President International Development Corporation — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C, Series D
- Maison Capital (https://capitalatlas.ai/funds/maison-capital) — Series C
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series C, Series D
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series C
- Sage Partners (https://capitalatlas.ai/funds/sage-partners) — Series C
- Mirae Asset Capital Markets (https://capitalatlas.ai/funds/mirae-asset-capital-markets) — Series C
- BOC International (https://capitalatlas.ai/funds/boc-international) — Series D
- WS Investments (https://capitalatlas.ai/funds/ws-investments) — Series D
- Aramco Ventures (https://capitalatlas.ai/funds/aramco-ventures) — Series D, Series E
- Wuxi Huading Venture Capital (https://capitalatlas.ai/funds/wuxi-huading-venture-capital) — Series E
- Value Partners Group (https://capitalatlas.ai/funds/value-partners-group) — Series E
- Pudong Venture Capital (https://capitalatlas.ai/funds/pudong-venture-capital) — Series E
- Yixing Yicai Private Equity Fund Management — Series E
- Shanghai Pudong Development (Group) Co., Ltd. — Series E
- Dahong Investment Co., Ltd. — Series E